Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,033 across all filing types
Latest filing 2026-05-23 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is a notice to stock exchanges detailing the logistics of an upcoming earnings call (date, time, dial-in numbers). It does not contain financial results or the transcript, nor is it an actual earnings release. It is a regulatory announcement for administrative purposes and does not fit specific categories like Earnings Release or Call Transcript. Therefore it falls under the general regulatory filings category (RNS).
2026-05-23 English
Enclosed please find herewith the details of Earnings Call slated for Monday, June 01, 2026 at 08:30 a.m. - 09:30 a.m. (IST) for your information and record.
Regulatory Filings Classification · 80% confidence The document is an invitation to an earnings call (listing date, time, dial-in details) without providing any actual financial results or highlights. It is a routine regulatory announcement to stock exchanges, not the earnings release itself, not the transcript, and contains no substantive financial data. Therefore, it falls under the miscellaneous regulatory announcement category (RNS).
2026-05-23 English
Settlement Agreement: Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015
Legal Proceedings Report Classification · 90% confidence The document is a stock exchange filing under Regulation 30 of SEBI LODR disclosing the settlement of antitrust and consumer-protection lawsuits. It provides details on legal proceedings and their resolution, with no financial statements beyond the settlement provision. This fits the “Legal Proceedings Report” category.
2026-05-23 English
General Updates
Legal Proceedings Report Classification · 90% confidence The document is a disclosure to stock exchanges under Regulation 30 of SEBI LODR concerning a settlement agreement in antitrust litigation. It provides details of legal proceedings and settlement terms rather than presenting financial results, corporate governance, or management changes. This aligns with a Legal Proceedings Report.
2026-05-23 English
Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors
Regulatory Filings Classification · 85% confidence The document is a stock exchange filing to BSE and NSE conveying a corporate press/media release announcing a new drug development candidate. It does not contain financial statements, voting results, or regulatory legal proceedings, nor is it an actual financial report. It is a general regulatory announcement (miscellaneous). Hence it falls under Regulatory Filings (RNS), the fallback category for miscellaneous announcements.
2026-05-20 English
Press Release
Regulatory Filings Classification · 82% confidence The document is a stock exchange filing to BSE and NSE announcing a new drug development candidate (ISB 2301) with an attached media release. It is not an actual financial report, earnings release, management change, or share transaction notice. There is no detailed financial data or period results. This falls into the fallback category of general regulatory announcements and filings that do not fit other categories.
2026-05-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.